Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study

BMC Cancer

Viktor H Koelzer²  Pia Herrmann¹  Inti Zlobec⁴  Eva Karamitopoulou²  Alessandro Lugli²  Ulrike Stein³ 

[1] Department of Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Strasse 10, Berlin, Germany

[2] Clinical Pathology Division, Institute of Pathology, University of Bern, Murtenstrasse 31, Bern, Switzerland

[3] German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, Heidelberg, Germany

[4] Translational Research Unit (TRU), Institute of Pathology, University of Bern, Murtenstrasse 31, Bern, Switzerland

关键词: Metastasis;    Prognostic factor;    Colorectal cancer;    Tumor budding;    Biomarker;    MACC1;   

Others  :  1143805
DOI  :  10.1186/s12885-015-1150-z

 received in 2014-11-05, accepted in 2015-02-27,  发布年份 2015

【 摘 要 】

Background

Metastasis of colorectal cancer (CRC) is directly linked to patient survival. We previously identified the novel gene Metastasis Associated in Colon Cancer 1 (MACC1) in CRC and demonstrated its importance as metastasis inducer and prognostic biomarker. Here, we investigate the geographic expression pattern of MACC1 in colorectal adenocarcinoma and tumor buds in correlation with clinicopathological and molecular features for improvement of survival prognosis.

Methods

We performed geographic MACC1 expression analysis in tumor center, invasive front and tumor buds on whole tissue sections of 187 well-characterized CRCs by immunohistochemistry. MACC1 expression in each geographic zone was analyzed with Mismatch repair (MMR)-status, BRAF/KRAS-mutations and CpG-island methylation.

Results

MACC1 was significantly overexpressed in tumor tissue as compared to normal mucosa (p < 0.001). Within colorectal adenocarcinomas, a significant increase of MACC1 from tumor center to front (p = 0.0012) was detected. MACC1 was highly overexpressed in 55% tumor budding cells. Independent of geographic location, MACC1 predicted advanced pT and pN-stages, high grade tumor budding, venous and lymphatic invasion (p < 0.05). High MACC1 expression at the invasive front was decisive for prediction of metastasis (p = 0.0223) and poor survival (p = 0.0217). The geographic pattern of MACC1 did not correlate with MMR-status, BRAF/KRAS-mutations or CpG-island methylation.

Conclusion

MACC1 is differentially expressed in CRC. At the invasive front, MACC1 expression predicts best aggressive clinicopathological features, tumor budding, metastasis formation and poor survival outcome.

【 授权许可】

   
2015 Koelzer et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
• [2]Stein U, Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007, 176:61-80.
• [3]Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al.: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009, 15(1):59-67.
• [4]Pichorner A, Sack U, Kobelt D, Kelch I, Arlt F, Smith J, et al.: In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice. Clin Exp Metastasis 2012, 29(6):573-83.
• [5]Nitsche U, Rosenberg R, Balmert A, Schuster T, Slotta-Huspenina J, Herrmann P, et al.: Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg 2012, 256(5):763-71. discussion 771
• [6]Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, et al.: Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS One 2012, 7(11):e49249.
• [7]Guo T, Yang J, Yao J, Zhang Y, Da M, Duan Y: Expression of MACC1 and c-Met in human gastric cancer and its clinical significance. Cancer Cell Int 2013, 13(1):121. BioMed Central Full Text
• [8]Wang JJ, Hong Q, Hu CG, Fang YJ, Wang Y: [Significance of MACC1 protein expression in esophageal carcinoma]. Zhonghua yi xue za zhi 2013, 93(32):2584-6.
• [9]Wang G, Kang MX, Lu WJ, Chen Y, Zhang B, Wu YL: MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncol Lett 2012, 4(4):783-91.
• [10]Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z, et al.: MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS One 2013, 8(5):e64235.
• [11]Gao S, Lin BY, Yang Z, Zheng ZY, Liu ZK, Wu LM, et al.: Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation. Int J Med Sci 2014, 11(3):268-75.
• [12]Ji D, Lu ZT, Li YQ, Liang ZY, Zhang PF, Li C, et al.: MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev 2014, 15(2):999-1003.
• [13]Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, et al.: Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 2011, 31(4):1141-5.
• [14]Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, et al.: Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 2011, 141(4):895-8.
• [15]Wang Z, Li Z, Wu C, Wang Y, Xia Y, Chen L, et al.: MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer. Med Oncol 2014, 31(1):790.
• [16]Sheng XJ, Li Z, Sun M, Wang ZH, Zhou DM, Li JQ, et al.: MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET. Oncol Lett 2014, 8(2):891-7.
• [17]Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, et al.: Overexpression of MACC1 and Its significance in human Breast Cancer Progression. Cell & Biosci 2013, 3(1):16. BioMed Central Full Text
• [18]Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, et al.: Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. Eur J Cancer 2014, 50(12):2134-41.
• [19]Hu H, Tian D, Chen T, Han R, Sun Y, Wu C: Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma. PLoS One 2014, 9(6):e100161.
• [20]Meng F, Li H, Shi H, Yang Q, Zhang F, Yang Y, et al.: MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/beta-catenin signaling pathway. PLoS One 2013, 8(4):e60821.
• [21]Yang T, Kong B, Kuang YQ, Cheng L, Gu JW, Zhang JH, et al.: Overexpression of MACC1 protein and its clinical implications in patients with glioma. Tumour Biol 2014, 35(1):815-9.
• [22]Hagemann C, Fuchs S, Monoranu CM, Herrmann P, Smith J, Hohmann T, et al.: Impact of MACC1 on human malignant glioma progression and patients’ unfavorable prognosis. Neuro Oncol 2013, 15(12):1696-709.
• [23]Zhang K, Zhang Y, Zhu H, Xue N, Liu J, Shan C, et al.: High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. Tumour Biol 2014, 35(2):1343-50.
• [24]Stein U: MACC1 - a novel target for solid cancers. Expert Opin Ther Targets 2013, 17(9):1039-52.
• [25]Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al.: Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol 2013, 44(5):697-705.
• [26]Karamitopoulou E, Zlobec I, Kolzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, et al.: Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol 2013, 26(2):295-301.
• [27]Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012, 10:51. BioMed Central Full Text
• [28]Ruschoff J, Nagelmeier I, Baretton G, Dietel M, Hofler H, Schildhaus HU, et al.: Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe 2010, 31(3):208-17.
• [29]Dawson H, Galvan JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, et al.: Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer J Int du Cancer 2014, 134(10):2342-51.
• [30]Perneger TV: What’s wrong with Bonferroni adjustments. BMJ 1998, 316(7139):1236-8.
• [31]Staub E, Groene J, Heinze M, Mennerich D, Roepcke S, Klaman I, et al.: Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. Mol Cancer 2007, 6:79. BioMed Central Full Text
• [32]Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, et al.: Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res 2008, 14(3):772-81.
• [33]Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H, et al.: MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway. Oncotarget 2014, 5(11):3756-69.
• [34]Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al.: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001, 98(18):10356-61.
• [35]Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al.: Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179(1–2):56-65.
• [36]Zlobec I, Lugli A: Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010, 1(7):651-61.
• [37]Christofori G: New signals from the invasive front. Nature 2006, 441(7092):444-50.
• [38]Bosman FT: World Health Organization., International Agency for Research on Cancer.: WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer, Lyon; 2010.
• [39]Gao J, Ding F, Liu Q, Yao Y: Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem 2013, 376(1–2):21-32.
• [40]Wang L, Wu Y, Lin L, Liu P, Huang H, Liao W, et al.: Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion. Int J Cancer J Int du Cancer 2013, 133(6):1419-30.
• [41]Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A: Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer 2013, 108(10):2088-96.
• [42]Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, et al.: The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology 2014, 64(4):577-84.
• [43]Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, et al.: MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 2014, 74(6):1857-69.
• [44]Mathias RA, Gopal SK, Simpson RJ: Contribution of cells undergoing epithelial-mesenchymal transition to the tumour microenvironment. J Proteomics 2013, 78:545-57.
• [45]Kin C, Kidess E, Poultsides GA, Visser BC, Jeffrey SS: Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn 2013, 13(6):581-99.
• [46]Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al.: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014, 259(4):735-43.
• [47]De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-62.